Azaindazoles useful as inhibitors of kinases

• US 8,445,681 B2
• Filed: 07/29/2011
• Issued: 05/21/2013
• Est. Priority Date: 11/15/2005
• Status: Expired due to Fees

• Current Assignee: Vertex Pharmaceuticals Incorporated
• Original Assignee: Vertex Pharmaceuticals Incorporated
• Inventors: Durrant, Steven, Knegtel, Ronald, Ramaya, Sharn, Keily, Shazia, Cao, Jingrong, Brenchley, Guy, Charrier, Jean-Damien
• Primary Examiner(s): O Dell, David K
• Application Number:
  US13/193,739
• Publication Number:
  US 20120165367A1
• Time in Patent Office: 662 Days
• Field of Search: 546/119, 514/303
• US Class Current: 546/119
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07D 471/02 in which the condensed system contains two hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/02 in which the condensed system contains two hetero rings

Abstract

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

Claims

1. A compound of formula I

2. The compound according to claim 1,

wherein R³ is H, CN, NO₂, halo, or a C_1-6alkylidene chain.

3. The compound according to claim 2, wherein R³ is H.

4. The compound according to claim 1, wherein R⁵ is H, CN, NO₂, halo, or a C_1-6alkylidene chain.

5. The compound according to claim 4, wherein R³ is H.

6. The compound according to claim 4, wherein R⁵ is H.

7. The compound according to claim 6, wherein R³ is H.

8. The compound according to claim 7, wherein R⁴ is H.

9. The compound according to claim 7, wherein R⁴ is (L⁴)_q-Z⁴.

10. The compound according to claim 1, wherein q is 0.

11. The compound according to claim 1, wherein q is 1.

12. The compound according to claim 11, wherein L⁴ is a C_1-6 alkylidene chain.

13. The compound of claim 1 selected from the following:

14. A composition comprising a compound of any one of claim 1 or claim 13, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.